Med-El has acquired two gene therapy programs from Rescue Hearing Inc targeting mutations in the MYO7A and STRC genes, expanding the hearing implant company’s pipeline into biological approaches to vestibular and auditory dysfunction....
No actionable change for current clinical practice; these gene therapy programs are pre-clinical pipeline acquisitions with no approved treatments available to patients yet.
This acquisition signals that major hearing implant manufacturers are betting on gene therapy as a future treatment pathway for genetic hearing loss, which could eventually reshape how audiologists counsel patients with hereditary hearing conditions.
- 01MED-EL has acquired two gene therapy programs from Rescue Hearing Inc.
- 02Programs target MYO7A and STRC gene mutations, both linked to inherited hearing loss.
- 03This marks MED-EL's first known expansion beyond hardware (implants) into biological/genetic treatments.
- 04The acquisition also covers potential treatments for vestibular (balance) dysfunction.
- 05No clinical availability timeline was disclosed; programs remain in the pipeline stage.
MED-EL acquired two gene therapy programs targeting MYO7A and STRC gene mutations from Rescue Hearing Inc.
press releasesupportedThe acquired programs target both auditory and vestibular dysfunction.
press releasepartially supportedThe acquisition expands MED-EL's pipeline beyond hearing implants into biological treatments.
press releasesupported